|
We asked 40 pharma leaders, should FDA be forced to make changes in how it regulates the drug industry?
Strongly agree |
44% |
Agree somewhat |
34% |
Disagree somewhat |
11% |
Disagree strongly |
11% |
 |
|
|
|
|
|
|
|
12 September, 2012
|
In this Issue |
 |
Women on Boards: A Pharma Perspective
The findings from a new study into women on boards within the European life sciences industry shows there is still work to be done, but suggest a better gender balance is within reach. Nick Stephens reports. Read more... |
Pharma Goes Soft on Social Media
Big Pharma's tin ear for social, user-generated content online is softening despite regulatory anxiety. In the quest to better understand what patients and doctors need, the industry is beginning to recognize and incorporate insights from social media into their development and commercialization programs. More... |
India's Piramal Pivots for Growth
Pharm Exec is startled by the raw-boned clarity of Piramal Healthcare's mission in this Interview with company chairman Ajay Piramal. There is only one goal: to become the first Indian company to discover, develop, and launch its own NCE for sale outside India. More... |
FDA Eyes More Foreign Inspections
FDA will soon be receiving a cash boost to help fund inspections of generic-drug manufacturing facilities via the implementation of the Generic Drug User Fee Amendments of 2012 (GDUFA), which comes into force on October 1, 2012. More...
|
Recruitment Profile |
Dessault Systems
Business Consultant Director Dassault Systèmes, the 3D Experience Company, provides business and people with virtual universes to imagine sustainable innovations. Its world-leading solutions transform the way products are designed, produced, and supported.
Read more |
|
 |
|
|